Euglena provides antibody testing service against new coronavirus (SARS-CoV-2)
Launched for medical institutions

Euglena Co., Ltd.
Leave a Nest Co., Ltd.
Made-to-order Medical Research Co., Ltd.

Euglena Co., Ltd. (President: Mitsuru Izumo, hereinafter "Euglena") is Leave a Nest Co., Ltd. (Vice President and CTO: Kiyoshi Inoue, hereinafter "Leave a Nest"), Custom-made Medical Research Co., Ltd. Provided to medical institutions an antibody test service * 1 for the new coronavirus SARS-CoV-2 (hereinafter "SARS-CoV-2"), which was jointly developed with Yasufumi (hereinafter "Made-to-order Medical Research"). I will start.
* 1 The start of joint development was announced on June 15, 2020 https://www.euglena.jp/news/20200615-2/

In the antibody test system for SARS-CoV-2 developed by the three companies so far, standard antibodies that react with the SARS-CoV-2 protein are produced, and not only qualitative positive / negative judgment but also anti-SARS-CoV -2 It is now possible to quantitatively estimate the antibody concentration * 2. Since then, the three companies have been studying to provide the developed antibody test system for SARS-CoV-2 as a service. And this time, we will provide the first service related to the antibody test system related to SARS-CoV-2 as an antibody test service Euglena Co., Ltd. to medical institutions * 3.​
* 2 Announced in the release dated July 6, 2020 https://www.euglena.jp/news/200818-2 /
* 3 This service is for medical institutions. Individuals will be able to receive this service through medical institutions such as hospitals and clinics that handle this service in the future.

■抗体検査サービスの内容
【特徴】
①　日本のバイオテックベンチャーがゼロから開発
本サービスは、検査方法の開発から解析までを全て国内で実施。日本の抗体医薬開発ベンチャーであるオーダーメードメディカルリサーチ社、リバネス社、ユーグレナ社の3社で共同開発した製品です。

② Accurate antibody detection even with a small amount of blood
This service uses blood as a biological sample for antibody testing. By optimizing the test process, it is possible to detect antibodies contained in blood with high sensitivity, and even a small amount of blood can be determined. Japanese data are used as the standard for the positive / negative judgment, and the positive predictive value and negative predictive value are 100% for the samples after the 11th day after the onset in the test. ※Four Has been confirmed to be.

③ Quantitative measurement of antibody amount
In this service, the amount of antibody can be measured by using the standard antibody developed independently, so it is possible to record the transition of the amount of antibody as well as the judgment of positive / negative. Compared to antibody tests that only show positive / negative judgment results, it is possible to regularly grasp the amount of antibody that increases or decreases over time.
* 4 Among clinical specimens that have obtained informed consent provided by medical institutions, as a result of performing an antibody test constructed for those that have received a positive test in the PCR test, they were collected 11 days after the onset. Positive tests were obtained in all of the clinical specimens. In addition, in the antibody test performed on clinical samples that were also negatively tested by PCR, all the samples were negative. This result shows that both the positive predictive value and the negative predictive value are 100% under the conditions of the test.

[Result image]
The dedicated web page provides results for the following items.
(1) Judgment result: The judgment result is displayed in 3 patterns (+ (antibody positive),- (antibody negative), ± (retest recommended)).
(2) Antibody amount: Semi-quantitative judgment is possible, and the transition of antibody amount can be confirmed by the graph.
(3) Detailed explanation: The content of the detailed explanation is selected and provided according to the inspection results.

Result notification image

【取扱いを希望される医療機関の方へ】
医療機関の方で取扱いをご検討される方はこちらへご連絡ください。
提供サイト：「ユーグレナ・マイヘルス」（https://myhealth.euglena.jp/products）
お問合せ先：shopmaster@myhealth.euglena.jp

<About Euglena Co., Ltd.>
In 2005, we succeeded in establishing the world's first edible outdoor mass culture technology for the Euglena A company listed on the First Section of the Tokyo Stock Exchange that develops and sells functional foods and cosmetics that utilize the Euglena produced on Ishigaki Island, and conducts research and development for biofuel production.
https://euglena.jp

<About Leave a Nest Co., Ltd.>
Based on the philosophy of "realizing the development of science and technology and contributing to the earth," we focus on science education, human resource development, research and development, and the creation of new businesses. Work on a typical project.
https://lne.st/

<About Custom-made Medical Research Co., Ltd.>
Professor Yasufumi Murakami of Tokyo University of Science launched and established the LIMAXYS method, an innovative antibody production technology. An antibody drug venture that has made it possible to produce membrane protein antibodies, which was difficult to produce until now.
https://www.omr.co.jp/

​ ​

-Contact for inquiries from the press-
Euglena Co., Ltd. Corporate Communication Division